{"id":790320,"date":"2024-11-25T07:05:30","date_gmt":"2024-11-25T12:05:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/"},"modified":"2024-11-25T07:05:30","modified_gmt":"2024-11-25T12:05:30","slug":"opthea-to-participate-in-citi-2024-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/","title":{"rendered":"Opthea to Participate in Citi 2024 Global Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MELBOURNE, Australia and PRINCETON, N.J., Nov.  25, 2024  (GLOBE NEWSWIRE) &#8212; Opthea Limited (ASX\/NASDAQ:OPT, \u201cOpthea\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Fred Guerard, PharmD, Chief Executive Officer, will host one-on-one meetings with investors and participate in a panel presentation during the Citi 2024 Global Healthcare Conference on December 5, 2024 in Miami, Florida.<\/p>\n<p align=\"justify\">Details are as follows:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:20%;width:20%;min-width:20%;vertical-align: bottom\">Panel:<\/td>\n<td style=\"max-width:80%;width:80%;min-width:80%;vertical-align: bottom\">Eyes Wide Open on Ophthalmology<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Presenter:<\/td>\n<td style=\"vertical-align: bottom\">Frederic Guerard, PharmD, CEO, Opthea<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Date:<\/td>\n<td style=\"vertical-align: bottom\">Thursday, December 5, 2024, 1:45 PM ET<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <br \/>The webcast will be accessible on the \u201cEvents &amp; Presentations\u201d section of the Company\u2019s website at http:\/\/ir.opthea.com\/.<\/p>\n<p align=\"justify\">\n        <strong>About Opthea<\/strong>\n      <\/p>\n<p align=\"justify\">Opthea (ASX\/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).<\/p>\n<p align=\"justify\">Opthea\u2019s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7povnp-kBcOGZscGuzoIlNcAIsyUs-aqzfisMsUtIePBBbtJ0SATLEkLLztnVnuKsnlXFGcsEeaOlFKMZkI0CfGMOijsHIjdsx8yvyxufoxAGGoJT2MBE-nXEfCwXZhOCBZNgSuE4Ds0mOQYZIySBw==\" rel=\"nofollow\" target=\"_blank\">NCT04757636<\/a>, and ShORe, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7povnp-kBcOGZscGuzoIlKfGTG9gUjf229LBZAAeQqnpCi7H7Z__sKhkBqj5-ADnKg0-RQktdxRfRXjWs-nkRBwyXPUZ70OykJuVpc4MSEqza-NNtQ2IT3t-mVUV7iW5s-Rq-lCfPoPBlLTGylaUDA==\" rel=\"nofollow\" target=\"_blank\">NCT04757610<\/a>) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.<\/p>\n<p align=\"justify\">To learn more, visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v1U0PMijzOqI8RQ8vHQJieEbqRba91xEaadqKMP4xhCj-iO1v_O62wuzxKn_Z0hzhx2V-YpAz9CzWqvFgeILGw==\" rel=\"nofollow\" target=\"_blank\">www.opthea.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XWxd6f_7NlYePp5_00QpSBxrtkNMLGKk7jWY-9cRHHacqVBusf6z1Vx77nwWWhF0iVcRDRMjWcUHzfoJKChMsA==\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gaYmYpuJgYPfm1hUTtSgfH9KQ1AawuI2QudzeCQdXy9CX8x99scLc4rxfAWmiR3dINqFDZqOXdQeK-XE4veqmL62kkWAxOnXSg1WUGjKDwA=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">Authorized for release to ASX by Frederic Guerard, PharmD, CEO<\/p>\n<p align=\"justify\">\n        <strong>Investor Inquiries<\/strong><br \/>\n        <br \/>PJ Kelleher\u00a0<br \/>LifeSci Advisors, LLC\u00a0<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0d4IG3tMBNhXE7oh3tobkNlqh8D19o7FgFZ3TiGV5R3nfhP1W3i7JaztL49lyhqJ9aEmV6L89fbFXL6xjTOUuXd8e_lUr2q2-tvxHm2ZRQhxPzgZxmY3XFeE20GwPT9h\" rel=\"nofollow\" target=\"_blank\">pkelleher@lifesciadvisors.com<\/a><br \/>Phone: 617-430-7579\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Media\u00a0Inquiries<\/strong>\u00a0<br \/>Silvana Guerci-Lena\u00a0<br \/>NorthStream Global Partners\u00a0<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xjJaSVUY4bJmsf2v7j-rhr7cfI6wM2WLbykeciSQAmAt6thtjhbuZkRJhforn01KnxZxV_t6-ejQZoz4Xj7KGWFAaY5XzEYbCKQkF-jMNis=\" rel=\"nofollow\" target=\"_blank\">silvana@nsgpllc.com<\/a>\u00a0<\/p>\n<p align=\"justify\">Join our email database to receive program updates:<br \/>Tel: +61 (0) 3 9826 0399, Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6vz3notxfqh3AjAypvzDyahUi767s4Uon-QOpJo2uUqmr_bGfxaHK7SBL8O6tQ32cbgEWUR_lRePJdWQt3uJAw==\" rel=\"nofollow\" target=\"_blank\"><u>info@opthea.com<\/u><\/a> Web: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v1U0PMijzOqI8RQ8vHQJiRSvhfLTKXiTVaWqApOnxqlkDYOwZj42cS6HIKBQe0S2m6UEOYWrQqquR2yjCa_1LQ==\" rel=\"nofollow\" target=\"_blank\"><u>www.opthea.com<\/u><\/a><br \/>Source: Opthea Limited<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI4OTI1MiM2NjA4NzQ0IzUwMDEyMTgwNg==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDc0ZTg0MmEtYWU0Mi00NTA4LTk5MmUtY2M1MGZmM2FiMjQ4LTUwMDEyMTgwNg==\/tiny\/Opthea-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MELBOURNE, Australia and PRINCETON, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) &#8212; Opthea Limited (ASX\/NASDAQ:OPT, \u201cOpthea\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Fred Guerard, PharmD, Chief Executive Officer, will host one-on-one meetings with investors and participate in a panel presentation during the Citi 2024 Global Healthcare Conference on December 5, 2024 in Miami, Florida. Details are as follows: Panel: Eyes Wide Open on Ophthalmology Presenter: Frederic Guerard, PharmD, CEO, Opthea Date: Thursday, December 5, 2024, 1:45 PM ET The webcast will be accessible on the \u201cEvents &amp; Presentations\u201d section of the Company\u2019s website at http:\/\/ir.opthea.com\/. About Opthea Opthea (ASX\/NASDAQ:OPT) is &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Opthea to Participate in Citi 2024 Global Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-790320","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Opthea to Participate in Citi 2024 Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Opthea to Participate in Citi 2024 Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MELBOURNE, Australia and PRINCETON, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) &#8212; Opthea Limited (ASX\/NASDAQ:OPT, \u201cOpthea\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Fred Guerard, PharmD, Chief Executive Officer, will host one-on-one meetings with investors and participate in a panel presentation during the Citi 2024 Global Healthcare Conference on December 5, 2024 in Miami, Florida. Details are as follows: Panel: Eyes Wide Open on Ophthalmology Presenter: Frederic Guerard, PharmD, CEO, Opthea Date: Thursday, December 5, 2024, 1:45 PM ET The webcast will be accessible on the \u201cEvents &amp; Presentations\u201d section of the Company\u2019s website at http:\/\/ir.opthea.com\/. About Opthea Opthea (ASX\/NASDAQ:OPT) is &hellip; Continue reading &quot;Opthea to Participate in Citi 2024 Global Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-25T12:05:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI4OTI1MiM2NjA4NzQ0IzUwMDEyMTgwNg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-participate-in-citi-2024-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-participate-in-citi-2024-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Opthea to Participate in Citi 2024 Global Healthcare Conference\",\"datePublished\":\"2024-11-25T12:05:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-participate-in-citi-2024-global-healthcare-conference\\\/\"},\"wordCount\":279,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-participate-in-citi-2024-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI4OTI1MiM2NjA4NzQ0IzUwMDEyMTgwNg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-participate-in-citi-2024-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-participate-in-citi-2024-global-healthcare-conference\\\/\",\"name\":\"Opthea to Participate in Citi 2024 Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-participate-in-citi-2024-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-participate-in-citi-2024-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI4OTI1MiM2NjA4NzQ0IzUwMDEyMTgwNg==\",\"datePublished\":\"2024-11-25T12:05:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-participate-in-citi-2024-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-participate-in-citi-2024-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-participate-in-citi-2024-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI4OTI1MiM2NjA4NzQ0IzUwMDEyMTgwNg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI4OTI1MiM2NjA4NzQ0IzUwMDEyMTgwNg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-participate-in-citi-2024-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Opthea to Participate in Citi 2024 Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Opthea to Participate in Citi 2024 Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Opthea to Participate in Citi 2024 Global Healthcare Conference - Market Newsdesk","og_description":"MELBOURNE, Australia and PRINCETON, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) &#8212; Opthea Limited (ASX\/NASDAQ:OPT, \u201cOpthea\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Fred Guerard, PharmD, Chief Executive Officer, will host one-on-one meetings with investors and participate in a panel presentation during the Citi 2024 Global Healthcare Conference on December 5, 2024 in Miami, Florida. Details are as follows: Panel: Eyes Wide Open on Ophthalmology Presenter: Frederic Guerard, PharmD, CEO, Opthea Date: Thursday, December 5, 2024, 1:45 PM ET The webcast will be accessible on the \u201cEvents &amp; Presentations\u201d section of the Company\u2019s website at http:\/\/ir.opthea.com\/. About Opthea Opthea (ASX\/NASDAQ:OPT) is &hellip; Continue reading \"Opthea to Participate in Citi 2024 Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2024-11-25T12:05:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI4OTI1MiM2NjA4NzQ0IzUwMDEyMTgwNg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Opthea to Participate in Citi 2024 Global Healthcare Conference","datePublished":"2024-11-25T12:05:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/"},"wordCount":279,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI4OTI1MiM2NjA4NzQ0IzUwMDEyMTgwNg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/","name":"Opthea to Participate in Citi 2024 Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI4OTI1MiM2NjA4NzQ0IzUwMDEyMTgwNg==","datePublished":"2024-11-25T12:05:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI4OTI1MiM2NjA4NzQ0IzUwMDEyMTgwNg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI4OTI1MiM2NjA4NzQ0IzUwMDEyMTgwNg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-participate-in-citi-2024-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Opthea to Participate in Citi 2024 Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/790320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=790320"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/790320\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=790320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=790320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=790320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}